TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28497325

Group type: EXPERIMENTAL
Intervention: PCIRV (Pressure-Controlled Inverse Ratio Ventilation) with I:E ratio of 1.5:1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PCIRV (Pressure-Controlled Inverse Ratio Ventilation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: VCV (Volume-Control Ventilation) with I:E ratio of 1:2
Number of subjects: 60
Study: 26124033

Group type: EXPERIMENTAL
Intervention: Tooth-borne hyrax appliance
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tooth-bone-borne hybrid hyrax appliance
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both appliances
Number of subjects: 25
Study: 23963965

Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride extended-release (XL) for 8 weeks
Number of subjects: 51
Study: 22073981

Group type: EXPERIMENTAL
Intervention: Classroom-based crew resource management (CRM) training, 2-day duration
Number of subjects: 6

Group type: COMPARATOR
Intervention: Matched control ICUs (no CRM training)
Number of subjects: 6
Study: 18795965

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 178
Study: 16403108

Group type: EXPERIMENTAL
Intervention: Emla (lignocaine 2.5% and prilocaine 2.5%)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Aqueous cream (placebo)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Emla
Number of subjects: 14
Study: 12793914

Group type: EXPERIMENTAL
Intervention: Heliox (helium/oxygen, 80:20)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 20
Study: 10449279

Group type: EXPERIMENTAL
Intervention: Once-daily didanosine (ddI) plus twice-daily stavudine (d4T)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Twice-daily didanosine (ddI) plus twice-daily stavudine (d4T)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 87
Study: 7605759

Group type: EXPERIMENTAL
Intervention: Alkalinized mepivacaine (1 mL sodium bicarbonate per 10 mL mepivacaine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline control (equal volume of saline added to mepivacaine)
Number of subjects: 40
Study: 2260046

Group type: EXPERIMENTAL
Intervention: Long-acting propranolol (LA.P) 160 mg once-daily
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 682655

Group type: EXPERIMENTAL
Intervention: Closed mitral commissurotomy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Open mitral commissurotomy
Number of subjects: 39
Study: 7138725

Group type: EXPERIMENTAL
Intervention: Air and 3-4% ether
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Air and 0.5% trichloroethylene
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxygen and intermittent i.v. morphine or pethidine
Number of subjects: 60
Study: 30882149

Group type: EXPERIMENTAL
Intervention: SNP-based model under control conditions
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: SNP-based model under water deficit conditions
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Statistical genomic prediction (GP) model under control conditions
Number of subjects: 267

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Water deficit conditions
Number of subjects: 267
Study: 30099583

Group type: EXPERIMENTAL
Intervention: Training by Vietnamese salon owners
Number of subjects: 200
Study: 26872295

Group type: EXPERIMENTAL
Intervention: Exercise (EX; 60 min at 60% maximal oxygen uptake)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON; without exercise)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both EX and CON
Number of subjects: 12
Study: 24451690

Group type: EXPERIMENTAL
Intervention: Horizontal hip joint angle (H-HJA) test
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Vertical hip joint angle (V-HJA) test
Number of subjects: 138

Group type: COMPARATOR
Intervention: Passive straight-leg raise (PSLR) test
Number of subjects: 138
Study: 22503020

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 200 U
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 300 U
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study: 20122366

Group type: EXPERIMENTAL
Intervention: quetiapine 300 mg/d
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: quetiapine 600 mg/d
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: paroxetine 20 mg/d
Number of subjects: 740

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 740
Study: 17327187

Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate-impregnated cloth (PC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4% chlorhexidine gluconate surgical skin preparation (SP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of PC and SP
Number of subjects: 30
Study: 15606444

Group type: EXPERIMENTAL
Intervention: Diclofenac-K 12.5 mg orally
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diclofenac-K 25 mg orally
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Diclofenac-K 22.5 mg via short-term i.v. infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: Comparison of 12.5 mg and 25 mg oral doses
Number of subjects: 10
Study: 11865964

Group type: EXPERIMENTAL
Intervention: 125 mg bosentan tablet (with food)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 125 mg bosentan tablet (without food)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Two tablets of 62.5 mg bosentan (with food)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Suspension of bosentan (without food)
Number of subjects: 16
Study: 10416558

Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (12 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 7555159

Group type: EXPERIMENTAL
Intervention: Anistreplase (30 U/5 min) + heparin
Number of subjects: 159

Group type: COMPARATOR
Intervention: Heparin-only therapy
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Persistently occluded vessel or increased coronary artery stenosis
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Reopened vessel or reduced coronary artery stenosis
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 159
Study: 2207562

Group type: EXPERIMENTAL
Intervention: Anterior lesser curve seromyotomy with posterior truncal vagotomy (AMPT, n = 77)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty (TVP, n = 69)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Anterior lesser curve seromyotomy with posterior truncal vagotomy (AMPT)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Truncal vagotomy and pyloroplasty (TVP)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Overall Visick grading
Number of subjects: 146
Study: 7386801

Group type: EXPERIMENTAL
Intervention: Sodium salicylate administration in large amounts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet devoid of salicylate-containing food
Number of subjects: 0
Study: 31358387

Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin
Number of subjects: 4203

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 4203

Group type: EXPERIMENTAL
Intervention: Both lutein and zeaxanthin and omega-3 fatty acids
Number of subjects: 4203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4203

Group type: EXPERIMENTAL
Intervention: Modified AREDS supplements (lower zinc dosage, omission of β-carotene, both, or no modification)
Number of subjects: 4203
Study: 27568392

Group type: EXPERIMENTAL
Intervention: Remote monitoring (Remote arm)
Number of subjects: 865

Group type: COMPARATOR
Intervention: Standard monitoring (Standard arm)
Number of subjects: 865
Study: 27231940

Group type: EXPERIMENTAL
Intervention: Onabotulintoxin A (BontA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution injection (Control)
Number of subjects: 20
Study: 24405257

Group type: EXPERIMENTAL
Intervention: Exercise with mechanical traction
Number of subjects: 86

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 86

Group type: COMPARATOR
Intervention: Exercise with over-door traction
Number of subjects: 86
Study: 21519221

Group type: EXPERIMENTAL
Intervention: New dose regimen of artesunate and amodiaquine (NDRAA)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Standard dose regimen of artesunate and amodiaquine (SDRAA)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Fixed-dose artesunate-amodiaquine (FDAA)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 304
Study: 19650425

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (0.05-1.5 W/cm2, 1 MHz frequency, 3-9 minutes per session, 10 sessions total)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (0.5-1.5 W/cm2, 4-9 minutes per session)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (10 patients without ultrasound influence)
Number of subjects: 29
Study: 17455439

Group type: EXPERIMENTAL
Intervention: Glass fiber‐reinforced post (FRP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metal screw posts (MSP)
Number of subjects: 100
Study: 15111679

Group type: EXPERIMENTAL
Intervention: Pergolide 0.25 to 0.75 mg in the evening for 6 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Open-label pergolide up to 1.5 mg/d for 12 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open-label pergolide after switching from placebo
Number of subjects: 100
Study: 11868930

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg and salmeterol 50 microg combination product (FSC) twice daily
Number of subjects: 432
Study: 9814494

Group type: EXPERIMENTAL
Intervention: Propranolol monotherapy after 7 days
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hyperthyroid state
Number of subjects: 42
Study: 7897129

Group type: EXPERIMENTAL
Intervention: Metoprolol (n = 16)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard therapy (n = 10)
Number of subjects: 26
Study: 2694229

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxiracetam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 324620

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide given continuously with methotrexate, 5‐fluorouracil, vincristine, and prednisone given intermittently
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cyclophosphamide given continuously
Number of subjects: 51
Study: 31470754

Group type: EXPERIMENTAL
Intervention: Matched intervention group (preferred intervention)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Mismatched intervention group (non-preferred intervention)
Number of subjects: 172
Study: 31411373

Group type: EXPERIMENTAL
Intervention: Turmeric-based beverage (TUR) before medium-fat (MF) breakfast
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Turmeric-based beverage (TUR) before high-fat (HF) breakfast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flavored water without turmeric before medium-fat (MF) breakfast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Flavored water without turmeric before high-fat (HF) breakfast
Number of subjects: 12
Study: 27785736

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin administered before a meal (30 min before a meal)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin administered before sleep
Number of subjects: 572

Group type: COMPARATOR
Intervention: Enteric-coated aspirin administered during a meal
Number of subjects: 572

Group type: COMPARATOR
Intervention: Enteric-coated aspirin administered after a meal (30 min after a meal)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin administered before a meal or before sleep
Number of subjects: 572

Group type: COMPARATOR
Intervention: Enteric-coated aspirin administered after a meal
Number of subjects: 572
Study: 25423326

Group type: EXPERIMENTAL
Intervention: Soy dietary supplement (90 mg of isoflavone)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose hormone therapy (1 mg of estradiol plus 0.5 mg of norethisterone)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 23315161

Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 259

Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 259
Study: 21712835

Group type: EXPERIMENTAL
Intervention: Inulin (24 g)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Glucose (75 g)
Number of subjects: 18
Study: 18494727

Group type: EXPERIMENTAL
Intervention: Scleral buckling without retinopexy (group 1)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Scleral buckling with retinal cryopexy (group 2)
Number of subjects: 55
Study: 17176177

Group type: EXPERIMENTAL
Intervention: Trauma-focused imaginal exposure
Number of subjects: 43

Group type: COMPARATOR
Intervention: Imagery-based relaxation
Number of subjects: 43
Study: 14521739

Group type: EXPERIMENTAL
Intervention: Ulinastatin 12,000 unit/kg (half given intravenously 10 min before aorta cannulation and half added into the priming fluid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal saline (same volume as ulinastatin)
Number of subjects: 20
Study: 11132019

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous Ambulatory Peritoneal Dialysis (CAPD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 60
Study: 8848324

Group type: EXPERIMENTAL
Intervention: 5 cm H2O of CPAP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 cm H2O of CPAP
Number of subjects: 10

Group type: COMPARATOR
Intervention: Zero end-expiratory pressure
Number of subjects: 10
Study: 1320887

Group type: EXPERIMENTAL
Intervention: Cyclosporin (CsA) at a dose of 7.5-10 mg/day for the first 6 months, then not exceeding 5 mg/kg/day thereafter
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 6392148

Group type: EXPERIMENTAL
Intervention: DTIC plus epirubicin (Epi‐DX) at a dose of 90 mg/m2 on day 1
Number of subjects: 42

Group type: COMPARATOR
Intervention: DTIC at a dose of 250 mg/m2/day 4 IV on days 1‐5
Number of subjects: 42
Study: 30165053

Group type: EXPERIMENTAL
Intervention: Tailored program of physical therapy focused on progressive training in strength, balance, and gait for a period of 3 months, including screening and referrals for low vision, polypharmacy, and environmental hazards.
Number of subjects: 354

Group type: COMPARATOR
Intervention: Usual care prescribed by a physician and educational materials on falls prevention.
Number of subjects: 354
Study: 29453502

Group type: EXPERIMENTAL
Intervention: Parenting Wisely program (various formats)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 311
Study: 26178580

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (5000 IU) + Calcium (600 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (Calcium alone)
Number of subjects: 20
Study: 26311340

Group type: COMPARATOR
Intervention: VARD (Group A; n=19)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: VARD+CBST (Group B; n=11)
Number of subjects: 30
Study: 23896665

Group type: COMPARATOR
Intervention: 30-cm intermittent catheter
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: 40-cm intermittent catheter
Number of subjects: 81
Study: 22015095

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg per day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg per day) in severe urticaria subgroup
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo in severe urticaria subgroup
Number of subjects: 22
Study: 18278702

Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study: 16957082

Group type: EXPERIMENTAL
Intervention: Negative connectivity within cortical and subcortical pathways to the amygdala
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive connections in a direct subcortical pathway to the amygdala
Number of subjects: 0
Study: 12684361

Group type: EXPERIMENTAL
Intervention: Zonisamide (n = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Zonisamide (n = 19)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 60
Study: 10959805

Group type: EXPERIMENTAL
Intervention: 6 or 9 million units (MU) interferon three times a week for 6 months (total dose: 468 or 702 MU)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 6MU of IFN over 6 months (total dose 564 MU)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 6 or 9 MU of IFN three times a week for 12 months (total dose: 936 or 1,404 MU)
Number of subjects: 114
Study: 8960446

Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg three times daily)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 8169401

Group type: EXPERIMENTAL
Intervention: Zidovudine (200 mg every 8 h) and fluconazole (400 mg daily) for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 12
Study: 2467134

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5-10.0 mg daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29265358

Group type: EXPERIMENTAL
Intervention: Cooperative Learning (CL) intervention
Number of subjects: 1460
Study: 27442085

Group type: EXPERIMENTAL
Intervention: SRP plus 1.2% Atorvastatin (ATV)
Number of subjects: 75

Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 75
Study: 25706516

Group type: EXPERIMENTAL
Intervention: AOK-proReha treatment approach
Number of subjects: 619
Study: 24717954

Group type: EXPERIMENTAL
Intervention: Quantic molecular resonance (QMR) inferior turbinoplasty in addition to standard medical treatment (ebastine, 10-mg tablet, and budesonide nasal spray at 100 micrograms/nostril per day for 90 days)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Standard medical treatment (ebastine, 10-mg tablet, and budesonide nasal spray at 100 micrograms/nostril per day for 90 days)
Number of subjects: 290
Study: 22648087

Group type: EXPERIMENTAL
Intervention: Staccato reperfusion plus statin therapy (SRSG)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Statin therapy plus abrupt reperfusion (SG)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Abrupt reperfusion alone (ARG)
Number of subjects: 47
Study: 20805570

Group type: EXPERIMENTAL
Intervention: Automated software analysis of corneal micrographs
Number of subjects: 0
Study: 18596271

Group type: EXPERIMENTAL
Intervention: Combination of 1 mg of epinephrine and 40 IU of vasopressin
Number of subjects: 2894

Group type: COMPARATOR
Intervention: Epinephrine alone (1 mg)
Number of subjects: 2894
Study: 15963746

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Gelofusine
Number of subjects: 40
Study: 11933905

Group type: EXPERIMENTAL
Intervention: Thermal-cycling at an upper temperature of 60 degrees C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Thermal-cycling at an upper temperature of 45 degrees C
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Thermal-cycling (both 45 degrees C and 60 degrees C)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Z100 and Surefil
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Thermal-cycling
Number of subjects: 18
Study: 9878938

Group type: EXPERIMENTAL
Intervention: Dalteparin 120 IU/kg body weight twice daily
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Dalteparin 7500 IU once daily (fixed dose)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Weight-adjusted treatment
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Fixed dose treatment
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Acute phase treatment
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Fixed-dose treatment
Number of subjects: 175
Study: 8822685

Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 20
Study: 1414432

Group type: EXPERIMENTAL
Intervention: Vaginal sponge use
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 72
Study: 4012191

Group type: EXPERIMENTAL
Intervention: Flunarizine (15 mg nocte)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pizotifen (1.5 mg nocte)
Number of subjects: 30
Study: 30590467

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 26

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 26
Study: 28836866

Group type: EXPERIMENTAL
Intervention: Azacitidine (Aza)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 36
Study: 26768928

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) 6 μg/kg/h for 10 min followed by 0.4 μg/kg/h until 5 min after extubation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (control) administered in a similar manner to Dex
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 70
Study: 24506231

Group type: EXPERIMENTAL
Intervention: Client-centred activities of daily living (CADL) intervention
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual activities of daily living (UADL) intervention
Number of subjects: 280
Study: 22678673

Group type: EXPERIMENTAL
Intervention: Single dose of akatinol memantine 20 mg in the morning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard treatment with two doses of akatinol memantine (10 mg in the morning and 10 mg in the afternoon)
Number of subjects: 40
Study: 20847991

Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 52

Group type: COMPARATOR
Intervention: Early loaded implants
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study: 17873686

Group type: EXPERIMENTAL
Intervention: XR-NTX 380 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: XR-NTX 190 mg
Number of subjects: 82
Study: 16383037

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 150 mg diammonium glycyrrhizinate per day for 14 days (T group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional treatment (C group)
Number of subjects: 20